1. Home
  2. ARDX vs DCBO Comparison

ARDX vs DCBO Comparison

Compare ARDX & DCBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARDX
  • DCBO
  • Stock Information
  • Founded
  • ARDX 2007
  • DCBO 2016
  • Country
  • ARDX United States
  • DCBO Canada
  • Employees
  • ARDX N/A
  • DCBO N/A
  • Industry
  • ARDX Biotechnology: Pharmaceutical Preparations
  • DCBO
  • Sector
  • ARDX Health Care
  • DCBO
  • Exchange
  • ARDX Nasdaq
  • DCBO Nasdaq
  • Market Cap
  • ARDX 1.3B
  • DCBO 893.8M
  • IPO Year
  • ARDX 2014
  • DCBO 2020
  • Fundamental
  • Price
  • ARDX $3.64
  • DCBO $32.03
  • Analyst Decision
  • ARDX Strong Buy
  • DCBO Strong Buy
  • Analyst Count
  • ARDX 8
  • DCBO 7
  • Target Price
  • ARDX $10.19
  • DCBO $48.14
  • AVG Volume (30 Days)
  • ARDX 6.4M
  • DCBO 67.4K
  • Earning Date
  • ARDX 05-01-2025
  • DCBO 05-09-2025
  • Dividend Yield
  • ARDX N/A
  • DCBO N/A
  • EPS Growth
  • ARDX N/A
  • DCBO 975.00
  • EPS
  • ARDX N/A
  • DCBO 0.86
  • Revenue
  • ARDX $361,706,000.00
  • DCBO $216,931,000.00
  • Revenue This Year
  • ARDX $15.74
  • DCBO $13.57
  • Revenue Next Year
  • ARDX $34.56
  • DCBO $13.40
  • P/E Ratio
  • ARDX N/A
  • DCBO $38.07
  • Revenue Growth
  • ARDX 127.33
  • DCBO 19.96
  • 52 Week Low
  • ARDX $3.62
  • DCBO $26.00
  • 52 Week High
  • ARDX $9.20
  • DCBO $53.86
  • Technical
  • Relative Strength Index (RSI)
  • ARDX 32.40
  • DCBO 56.21
  • Support Level
  • ARDX $3.62
  • DCBO $31.25
  • Resistance Level
  • ARDX $5.65
  • DCBO $32.11
  • Average True Range (ATR)
  • ARDX 0.31
  • DCBO 0.90
  • MACD
  • ARDX -0.15
  • DCBO 0.29
  • Stochastic Oscillator
  • ARDX 6.53
  • DCBO 69.83

About ARDX Ardelyx Inc.

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

Share on Social Networks: